Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
6.10
0.00 (0.00%)
Aug 10, 2026, 11:29 AM EDT - Market open
Wave Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 368.01 | 602.07 | 302.08 | 200.35 | 88.5 | 150.56 |
Short-Term Investments | 122.59 | - | - | - | - | - |
Cash & Short-Term Investments | 490.6 | 602.07 | 302.08 | 200.35 | 88.5 | 150.56 |
Cash Growth | 135.32% | 99.31% | 50.77% | 126.39% | -41.22% | -18.39% |
Accounts Receivable | 0.89 | 1.28 | 1.42 | 21.09 | - | - |
Other Current Assets | 16.02 | 11.47 | 16.89 | 13.94 | 10.04 | 12 |
Total Current Assets | 507.51 | 614.81 | 320.39 | 235.37 | 98.54 | 162.56 |
Net Property, Plant & Equipment | 46.33 | 19.86 | 28 | 35.72 | 44.13 | 40.64 |
Other Long-Term Assets | 4.48 | 3.82 | 3.82 | 3.86 | 3.72 | 3.8 |
Total Assets | 558.32 | 638.5 | 352.21 | 274.95 | 146.39 | 207.01 |
Accounts Payable | 20.36 | 15.7 | 16.26 | 12.84 | 16.92 | 7.28 |
Accrued Expenses | 18.24 | 26.56 | 21.08 | 16.83 | 17.55 | 14.86 |
Current Portion of Leases | 3.51 | 8.36 | 7.64 | 6.71 | 5.5 | 4.96 |
Unearned Revenue | 8.7 | 44.44 | 65.97 | 150.06 | 31.56 | 37.1 |
Total Current Liabilities | 50.82 | 95.07 | 110.95 | 186.44 | 71.52 | 64.2 |
Long-Term Leases | 40.08 | 9.41 | 17.77 | 25.4 | 32.12 | 24.96 |
Other Long-Term Liabilities | 13.9 | 7.8 | 6.1 | 15.6 | 79.96 | 77.48 |
Total Long-Term Liabilities | 53.99 | 17.2 | 23.87 | 41.01 | 112.08 | 102.43 |
Total Liabilities | 104.8 | 112.27 | 134.82 | 227.45 | 183.6 | 166.64 |
Common Stock | 1,627 | 1,616 | 1,175 | 935.37 | 802.83 | 749.85 |
Additional Paid-in Capital | 248.16 | 228.37 | 156.45 | 129.24 | 119.44 | 87.98 |
Accumulated Other Comprehensive Income | -0.17 | -0.25 | -0.26 | -0.12 | -0.03 | 0.18 |
Retained Earnings | -1,422 | -1,326 | -1,122 | -1,025 | -967.34 | -805.51 |
Total Common Shareholders' Equity | 453.52 | 518.36 | 209.52 | 39.63 | -45.09 | 32.5 |
Minority Interest | - | 7.87 | 7.87 | 7.87 | 7.87 | 7.87 |
Shareholders' Equity | 453.52 | 526.23 | 217.39 | 47.5 | -37.22 | 40.37 |
Total Liabilities & Equity | 558.32 | 638.5 | 352.21 | 274.95 | 146.39 | 207.01 |
Total Debt | 43.59 | 17.77 | 25.4 | 32.12 | 37.61 | 29.92 |
Net Cash (Debt) | 447.01 | 584.3 | 276.67 | 168.23 | 50.88 | 120.65 |
Net Cash Growth | 139.34% | 111.19% | 64.46% | 230.63% | -57.83% | -22.26% |
Net Cash Per Share | 2.38 | 3.46 | 2.00 | 1.59 | 0.65 | 2.33 |
Book Value | 453.52 | 518.36 | 209.52 | 39.63 | -45.09 | 32.5 |
Book Value Per Share | 2.41 | 3.07 | 1.52 | 0.37 | -0.57 | 0.63 |
Tangible Book Value | 453.52 | 518.36 | 209.52 | 39.63 | -45.09 | 32.5 |
Tangible Book Value Per Share | 2.41 | 3.07 | 1.52 | 0.37 | -0.57 | 0.63 |